Ricardo Dolmetsch is the founder of Tempero Bio. Tempero Bio has raised $70M in total funding. Latest round: Series B. Based in Oakland, California, US.
Ricardo Dolmetsch, Ph.D., serves as President and Chief Scientific Officer of Tempero Bio, a clinical-stage biopharmaceutical company based in Oakland, California. The company focuses on developing treatments for substance use disorders, with its lead candidate TMP-301 targeting alcohol and cocaine use disorders. Tempero Bio recently secured $70 million in Series B financing to advance TMP-301 into Phase 2 clinical trials.
Full founder directory · Investor directory · Company funding database · Fundraising library